26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
14 February 20224th Bacteriophage Therapy SummitThe definitive gathering of global phage experts across disciplines and industries is back. Focusing on human health and disease, advance…read more >>
26 January 2022Human – Animal One Health: At the Confluence of human & veterinary public health«The One Health Concept: At the confluence of human and veterinary public health» aims to bring together researchers, industrial stakeholders and…read more >>
26 January 2022REVIVE Webinar: New technologies and strategies to overcome the challenges of sexually transmitted infectionsREVIVE is a space for everybody with an interest in antimicrobial R&D.read more >>
19 January 2022REVIVE Webinar: Target candidate profiles and target product profiles for new antimicrobialsREVIVE is a space for everybody with an interest in antimicrobial R&D.read more >>
10 January 2022Biotech Showcase 2022 (In-person & Virtual Event)Engage with Global investors & Life Sciences Executives! Join us from January 10–12, 2022 in San Francisco, or Join us…read more >>
09 December 2021SCT Virtual Symposium: On the hunt for next generation antimicrobial agentsAn exciting two-day symposium entitled: On the hunt for next generation antimicrobial agents. This symposium will bring together some of…read more >>
23 November 2021Phage futures Europe: Translating phage-based applications into clinically and commercially viable therapeuticsSeeing the news that Proteon Pharmaceuticals secured a €21 million investment was an exciting moment. It is another backing in…read more >>
19 November 2021REVIVE Webinar: The roles of different actors in developing new treatments for drug-resistant infectionsThis World Antimicrobial Awareness Week, GARDP, together with WHO, will be holding an AMR Discussions webinar in which a panel…read more >>
17 November 20216th Annual Microbiome Connect: Gut TherapeuticsThis event is a unique gathering of individuals from academia and industry who are collaborating to advance microbiome science.read more >>
